CN100506232C - 用于治疗眼压过高和青光眼的组合物 - Google Patents

用于治疗眼压过高和青光眼的组合物 Download PDF

Info

Publication number
CN100506232C
CN100506232C CNB018093396A CN01809339A CN100506232C CN 100506232 C CN100506232 C CN 100506232C CN B018093396 A CNB018093396 A CN B018093396A CN 01809339 A CN01809339 A CN 01809339A CN 100506232 C CN100506232 C CN 100506232C
Authority
CN
China
Prior art keywords
group
prostaglandin
hydroxyl
aryl
chemical compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018093396A
Other languages
English (en)
Chinese (zh)
Other versions
CN1429112A (zh
Inventor
上野隆司
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/730,830 external-priority patent/US20010034355A1/en
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Publication of CN1429112A publication Critical patent/CN1429112A/zh
Application granted granted Critical
Publication of CN100506232C publication Critical patent/CN100506232C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB018093396A 2000-03-16 2001-03-15 用于治疗眼压过高和青光眼的组合物 Expired - Fee Related CN100506232C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US52757300A 2000-03-16 2000-03-16
US09/527,573 2000-03-16
US09/730,830 2000-12-07
US09/730,830 US20010034355A1 (en) 2000-03-16 2000-12-07 Treatment of ocular hypertension

Publications (2)

Publication Number Publication Date
CN1429112A CN1429112A (zh) 2003-07-09
CN100506232C true CN100506232C (zh) 2009-07-01

Family

ID=27062443

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018093396A Expired - Fee Related CN100506232C (zh) 2000-03-16 2001-03-15 用于治疗眼压过高和青光眼的组合物

Country Status (18)

Country Link
US (1) US20010056104A1 (https=)
EP (1) EP1272194A2 (https=)
JP (1) JP2003526660A (https=)
KR (1) KR20080012407A (https=)
CN (1) CN100506232C (https=)
AR (1) AR029818A1 (https=)
AU (2) AU4114301A (https=)
BR (1) BR0109192A (https=)
CA (1) CA2402597C (https=)
CZ (1) CZ20023092A3 (https=)
HU (1) HUP0300391A3 (https=)
IL (1) IL151683A0 (https=)
MX (1) MXPA02008967A (https=)
NO (1) NO20024381L (https=)
NZ (1) NZ521325A (https=)
RU (1) RU2002127733A (https=)
TW (1) TWI286932B (https=)
WO (1) WO2001068072A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL124620A0 (en) † 1995-12-18 1998-12-06 Myriad Genetics Inc Chromosome 13-linked breast cancer susceptibility gene
US20020035148A1 (en) * 2000-07-20 2002-03-21 Ryuji Ueno Treatment of ocular hypertension
US6713268B2 (en) * 2001-06-26 2004-03-30 Allergan, Inc. Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
CA2454422A1 (en) * 2001-07-31 2003-02-13 Ryuji Ueno Treatment of ocular hypertension and glaucoma
AU2003215820A1 (en) * 2002-03-28 2003-10-13 Sucampo Ag Method for treating ocular hypertension and glaucoma

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
WO1999051273A1 (en) * 1998-04-07 1999-10-14 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6030999A (en) * 1988-09-06 2000-02-29 Pharmacia & Upjohn Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3850676T2 (de) * 1987-09-18 1994-11-03 Ueno Seiyaku Oyo Kenkyujo Kk Hypotensive okulare Mittel.
TW224942B (https=) * 1990-04-04 1994-06-11 Adka Ueno Kk
AU687906B2 (en) * 1993-12-15 1998-03-05 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
AU7680096A (en) * 1995-12-22 1997-07-17 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
US6232344B1 (en) * 1997-12-22 2001-05-15 Alcon Laboratories, Inc. 13-Oxa prostaglandins for the treatment of glaucoma and ocular hypertension

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6030999A (en) * 1988-09-06 2000-02-29 Pharmacia & Upjohn Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
WO1999051273A1 (en) * 1998-04-07 1999-10-14 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum

Also Published As

Publication number Publication date
JP2003526660A (ja) 2003-09-09
NZ521325A (en) 2004-05-28
AR029818A1 (es) 2003-07-16
AU2001241143B2 (en) 2005-08-25
WO2001068072A2 (en) 2001-09-20
MXPA02008967A (es) 2003-02-12
AU4114301A (en) 2001-09-24
CA2402597A1 (en) 2001-09-20
CA2402597C (en) 2011-04-26
WO2001068072A3 (en) 2002-06-06
CZ20023092A3 (cs) 2003-05-14
NO20024381L (no) 2002-11-15
HUP0300391A3 (en) 2008-05-28
EP1272194A2 (en) 2003-01-08
CN1429112A (zh) 2003-07-09
RU2002127733A (ru) 2004-03-27
HUP0300391A2 (hu) 2003-06-28
IL151683A0 (en) 2003-04-10
NO20024381D0 (no) 2002-09-13
TWI286932B (en) 2007-09-21
BR0109192A (pt) 2003-05-27
KR20080012407A (ko) 2008-02-11
US20010056104A1 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
JP5213448B2 (ja) 末梢血管疾患の処置のための方法および組成物
JP2011512323A (ja) 幹細胞の成長を調節するための方法および組成物
JP2004504350A (ja) 高眼圧症および緑内障処置用組成物
CN100506232C (zh) 用于治疗眼压过高和青光眼的组合物
KR101118935B1 (ko) 안과용 조성물
US6458836B1 (en) Treatment of ocular hypertension and glaucoma
JP2004529177A (ja) 高眼圧症および緑内障の処置方法
KR20140035363A (ko) 안정피로 치료 방법
KR20120018158A (ko) 황반변성을 치료하기 위한 방법 및 조성물
AU2001241143A1 (en) Composition for use in treatment of ocular hypertension and glaucoma
JP2004521960A (ja) 高眼圧症および緑内障の処置のための方法および組成物
TW200418490A (en) Composition for treating ocular hypertension and glaucoma technical field
ZA200207140B (en) Treatment of ocular hypertension and glaucoma.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090701

Termination date: 20160315